CD146在血脑屏障中的作用及其机制研究进展

doi:10.3969/j.issn.1672-6731.2020.10.002

中国现代神经疾病杂志 ›› 2020, Vol. 20 ›› Issue (10): 848-852. doi: 10.3969/j.issn.1672-6731.2020.10.002

2 CD146在血脑屏障中的作用及其机制研究进展

王大吉¹, 段红霞², 聂国辉¹, 阎锡蕴², 郝洪军³

1 518035 广东省深圳市第二人民医院深圳大学第一附属医院转化医学研究院;
2 100012 北京, 中国科学院生物物理研究所蛋白质与多肽药物重点实验室;
3 100034 北京大学第一医院神经内科

收稿日期:2020-09-22 出版日期:2020-10-25 发布日期:2020-10-30
通讯作者: 聂国辉,Email:nieguohui@email.szu.edu.cn;阎锡蕴,Email:yanxy@ibp.ac.cn;郝洪军,Email:haohj1963@126.com
基金资助:
国家自然科学基金重大研究计划项目（项目编号：91529306）；国家自然科学基金青年科学基金资助项目（项目编号：81502547）

Research progress of the role and mechanism of CD146 in blood brain barrier

WANG Da-ji¹, DUAN Hong-xia², NIE Guo-hui¹, YAN Xi-yun², HAO Hong-jun³

1 Institute of Translational Medicine, Shenzhen Second People's Hospital;the First Affiliated Hospital of Shenzhen University, Shenzhen 518035, Guangdong, China;
2 Key Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100012, China;
3 Department of Neurology, Peking University First Hospital, Beijing 100034, China

Received:2020-09-22 Online:2020-10-25 Published:2020-10-30
Supported by:
This study was supported by the National Natural Science Foundation of China Major Research Programs (No. 91529306) and the National Natural Science Foundation of China for Young Scientists (No. 81502547).

摘要/Abstract

摘要：

细胞黏附分子CD146是免疫球蛋白超家族成员，最初被认为是黑色素瘤标志物，后续研究发现CD146是新生血管标志物，随着血管的成熟，其表达水平显著下降或不表达，提示其在血管发育和成熟中的重要作用。近年大量文献报道CD146及其可溶形式参与血脑屏障发育和病理性损害过程，本文拟对CD146在血脑屏障中的作用及其机制进行概述，有助于深入探寻CD146在多种血脑屏障损害相关颅内疾病中的潜在价值。

关键词: 神经细胞黏附分子类, 血脑屏障, 炎症, 中枢神经系统, 综述

Abstract:

Cell adhesion molecule CD146 belonging to the immune-globulin superfamily member, was initially identified as a melanoma marker. With the development of CD146 research, it was found that CD146 is a neovascularization marker. The CD146 expression is decreased significantly or absent following with the maturation of blood vessels, indicating the critical role of CD146 in the development and maturation of blood vessels. In recent years, numerous studies have reported that CD146 and its soluble form (sCD146) are involved in development and pathological damage of blood brain barrier (BBB). This paper aims to review the role and mechanism of CD146 in BBB. It will be helpful to further explore the potential value of CD146 in various BBB damage-related brain diseases.

Key words: Neural cell adhesion molecules, Blood-brain barrier, Inflammation, Central nervous system, Review

王大吉, 段红霞, 聂国辉, 阎锡蕴, 郝洪军. CD146在血脑屏障中的作用及其机制研究进展[J]. 中国现代神经疾病杂志, 2020, 20(10): 848-852.

WANG Da-ji, DUAN Hong-xia, NIE Guo-hui, YAN Xi-yun, HAO Hong-jun. Research progress of the role and mechanism of CD146 in blood brain barrier[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2020, 20(10): 848-852.

http://journal11.magtechjournal.com/cjcnn/CN/Y2020/V20/I10/848

参考文献

[1] Lehmann JM, Holzmann B, Breitbart EW, Schmiegelow P, Riethmüller G, Johnson JP. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113, 000 and a protein with a molecular weight of 76, 000[J]. Cancer Res, 1987, 47:841-845.
[2] Shih IM, Nesbit M, Herlyn M, Kurman RJ. A new Mel-CAM (CD146)-specific monoclonal antibody, MN-4, on paraffin-embedded tissue[J]. Mod Pathol, 1998, 11:1098-1106.
[3] Zeng P, Li H, Lu PH, Zhou LN, Tang M, Liu CY, Chen MB. Prognostic value of CD146 in solid tumor:a systematic review and Meta-analysis[J]. Sci Rep, 2017, 7:4223.
[4] Bardin N, George F, Mutin M, Brisson C, Horschowski N, Frances V, Lesaule G, Sampol J. S-Endo 1, a pan-endothelial monoclonal antibody recognizing a novel human endothelial antigen[J]. Tissue Antigens, 1996, 48:531-539.
[5] Shih IM, Elder DE, Speicher D, Johnson JP, Herlyn M. Isolation and functional characterization of the A32 melanoma-associated antigen[J]. Cancer Res, 1994, 54:2514-2520.
[6] Wang Z, Xu Q, Zhang N, Du X, Xu G, Yan X. CD146, from a melanoma cell adhesion molecule to a signaling receptor[J]. Signal Transduct Target Ther, 2020, 5:148.
[7] Yan X, Lin Y, Yang D, Shen Y, Yuan M, Zhang Z, Li P, Xia H, Li L, Luo D, Liu Q, Mann K, Bader BL. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth[J]. Blood, 2003, 102:184-191.
[8] Jiang T, Zhuang J, Duan H, Luo Y, Zeng Q, Fan K, Yan H, Lu D, Ye Z, Hao J, Feng J, Yang D, Yan X. CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis[J]. Blood, 2012, 120:2330-2339.
[9] Pariyawathee S, Phattarataratip E, Thongprasom K. CD146 expression in oral lichen planus and oral cancer[J]. Clin Oral Investig, 2020, 24:325-332.
[10] Breuer J, Korpos E, Hannocks MJ, Schneider-Hohendorf T, Song J, Zondler L, Herich S, Flanagan K, Korn T, Zarbock A. Blockade of MCAM/CD146 impedes CNS infiltration of T cells over the choroid plexus[J]. J Neuroinflamm, 2018, 15:236.
[11] Neidhart M, Wehrli R, Bruhlmann P, Michel BA, Gay RE, Gay S. Synovial fluid CD146(MUC18), a marker for synovial membrane angiogenesis in rheumatoid arthritis[J]. Arthritis Rheum, 1999, 42:622-630.
[12] Tsiolakidou G, Koutroubakis IE, Tzardi M, Kouroumalis EA. Increased expression of VEGF and CD146 in patients with inflammatory bowel disease[J]. Dig Liver Dis, 2008, 40:673-679.
[13] Bardin N, Reumaux D, Geboes K, Colombel JF, Blot-Chabaud M, Sampol J, Duthilleul P, Dignat-George F. Increased expression of CD146, a new marker of the endothelial junction in active inflammatory bowel disease[J]. Inflamm Bowel Dis, 2006, 12:16-21.
[14] Boratyńska M, Karbowska A, Klinger M. The effect of hyperuricemia on endothelial biomarkers and renal function in kidney allograft recipients[J]. Transplant Proc, 2010, 42:4074-4077.
[15] Malyszko J, Malyszko JS, Brzosko S, Wolczynski S, Mysliwiec M. Markers of endothelial cell activation/injury:CD146 and thrombomodulin are related to adiponectin in kidney allograft recipients[J]. Am J Nephrol, 2005, 25:203-210.
[16] Li L, Zhang BR, Zeng XF, Wang X. A pilot study on the significance of leucocyte CD146 expression in vasculitis[J]. Zhonghua Nei Ke Za Zhi, 2006, 45:748-751. [李玲, 张佰茹, 曾小峰, 汪玄. CD146在血管炎患者外周血白细胞表达的意义初探[J]. 中华内科杂志, 2006, 45:748-751.]
[17] Pollak TA, Drndarski S, Stone JM, David AS, McGuire P, Abbott NJ. The blood-brain barrier in psychosis[J]. Lancet Psychiatry, 2018, 5:79-92.
[18] Obermeier B, Verma A, Ransohoff RM. The blood-brain barrier[J]. Handb Clin Neurol, 2016, 133:39-59.
[19] Goasdoué K, Miller SM, Colditz PB, Björkman ST. Review:the blood-brain barrier; protecting the developing fetal brain[J]. Placenta, 2017, 54:111-116.
[20] Bauer H, Traweger A. Tight junctions of the blood-brain barrier:a molecular gatekeeper[J]. CNS Neurol Disord Drug Targets, 2016, 15:1016-1029.
[21] Lochhead JJ, Yang J, Ronaldson PT, Davis TP. Structure, function, and regulation of the blood-brain barrier tight junction in central nervous system disorders[J]. Front Physiol, 2020, 11:914.
[22] Grieb P, Forster RE, Strome D, Goodwin CW, Pape PC.O2 exchange between blood and brain tissues studied with 18O2 indicator-dilution technique[J]. J Appl Physiol, 1985, 58:1929-1941.
[23] Pardridge WM, Eisenberg J, Yang J. Human blood brain barrier insulin receptor[J]. J Neurochem, 1985, 44:1771-1778.
[24] Zhang Y, Pardridge WM. Rapid transferrin efflux from brain to blood across the blood brain barrier[J]. J Neurochem, 2001, 76:1597-1600.
[25] Wrobel JK, Toborek M. Blood-brain barrier remodeling during brain metastasis formation[J]. Mol Med, 2016, 22:32-40.
[26] Lagana P, Soraci L, Gambuzza ME, Mancuso G, Delia SA. Innate immune surveillance in the central nervous system following Legionella pneumophila infection[J]. CNS Neurol Disord Drug Targets, 2017, 16:1080-1089.
[27] Langen UH, Ayloo S, Gu C. Development and cell biology of the blood-brain barrier[J]. Annu Rev Cell Dev Biol, 2019, 35:591-613.
[28] Chen J, Luo Y, Hui H, Cai T, Huang H, Yang F, Feng J, Zhang J, Yan X. CD146 coordinates brain endothelial cell-pericyte communication for blood-brain barrier development[J]. Proc Natl Acad Sci USA, 2017, 114:E7622-7631.
[29] Chen J, Luo Y, Huang H, Wu S, Feng J, Zhang J, Yan X. CD146 is essential for PDGFRbeta-induced pericyte recruitment[J]. Protein Cell, 2018, 9:743-747.
[30] Yang C, Hawkins KE, Doré S, Candelario-Jalil E. Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke[J]. Am J Physiol Cell Physiol, 2019, 316:C135-153.
[31] Ueno M, Chiba Y, Matsumoto K, Murakami R, Fujihara R, Kawauchi M, Miyanaka H, Nakagawa T. Blood-brain barrier damage in vascular dementia[J]. Neuropathology, 2016, 36:115-124.
[32] Nation DA, Sweeney MD, Montagne A, Sagare AP, D'Orazio LM, Pachicano M, Sepehrband F, Nelson AR, Buennagel DP, Harrington MG. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction[J]. Nat Med, 2019, 25:270-276.
[33] Stolp HB, Dziegielewska KM. Review:role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases[J]. Neuropath Appl Neurobiol, 2009, 35:132-146.
[34] Ek CJ, Dziegielewska KM, Stolp H, Saunders NR. Functional effectiveness of the blood-brain barrier to small water soluble molecules in developing and adult opossum (Monodelphisdomestica)[J]. J Comp Neurol, 2006, 496:13-26.
[35] Kolbinger F, Huppertz C, Mir A, Padova FD. IL-17A and multiple sclerosis:signaling pathways, producing cells and target cells in the central nervous system[J]. Curr Drug Targets, 2016, 17:1882-1893.
[36] Wagner CA, Roqué PJ, Goverman JM. Pathogenic T cell cytokines in multiple sclerosis[J]. J Exp Med, 2020, 217:e20190460.
[37] Duan H, Xing S, Luo Y, Feng L, Gramaglia I, Zhang Y, Lu D, Zeng Q, Fan K, Feng J, Yang D, Qin Z, Couraud PO, Romero IA, Weksler B, Yan X. Targeting endothelial CD146 attenuates neuroinflammation by limiting lymphocyte extravasation to the CNS[J]. Sci Rep, 2013, 3:1687.
[38] Duan H, Luo Y, Hao H, Feng L, Zhang Y, Lu D, Xing S, Feng J, Yang D, Song L, Yan X. Soluble CD146 in cerebrospinal fluid of active multiple sclerosis[J]. Neuroscience, 2013, 235:16-26.
[39] Wang D, Duan H, Feng J, Xiang J, Feng L, Liu D, Chen X, Jing L, Liu Z, Zhang D, Hao H, Yan X. Soluble CD146, a cerebrospinal fluid marker for neuroinflammation, promotes blood-brain barrier dysfunction[J]. Theranostics, 2020, 10:231-246.

选择文件类型/文献管理软件名称

选择包含的内容

2 CD146在血脑屏障中的作用及其机制研究进展

Research progress of the role and mechanism of CD146 in blood brain barrier

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	薛蓉, 张轩. 睡眠障碍对脑血管病的影响[J]. 中国现代神经疾病杂志, 2023, 23(8): 659-662.
[2]	张鹏, 陈涛, 许莉. 成人失眠认知行为疗法关键技术与流程改进建议[J]. 中国现代神经疾病杂志, 2023, 23(8): 663-667.
[3]	张轩, 薛蓉. 特发性快速眼动睡眠期行为障碍向神经系统变性疾病转化的生物学标志物研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 668-673.
[4]	刘引, 汤永红, 翟锦霞, 邱媛. 慢性低度炎症与睡眠障碍研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 674-677.
[5]	于洁洋, 张亚男, 李惠敏, 黄真灿, 李宛儒, 王赞. 发作性睡病与焦虑研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 678-682.
[6]	库成心, 邓丽影, 谢亮. 缺血性卒中继发日间过度思睡研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 683-686.
[7]	姜佳凤, 赵莲花, 赵伟. 褪黑素在阿尔茨海默病病理损害机制中的作用[J]. 中国现代神经疾病杂志, 2023, 23(8): 687-692.
[8]	黄沛, 王刚. 功能性帕金森综合征诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(8): 738-741.
[9]	洪涛, 唐斌. 如何成为一名优秀的颅底外科医师[J]. 中国现代神经疾病杂志, 2023, 23(7): 571-574.
[10]	张庆硕, 宋丹丹, 周世越, 张金璐, 韩晓旭, 许顺良. 功能性步态障碍诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(7): 604-609.
[11]	潘希娟, 邢英琦, 刘玉梅. 脑小血管病影像学评分方法[J]. 中国现代神经疾病杂志, 2023, 23(7): 633-637.
[12]	俞淑凤, 李宁, 徐健, 王鹏. 颈动脉漂浮血栓相关缺血性卒中诊断与治疗进展[J]. 中国现代神经疾病杂志, 2023, 23(7): 638-642.
[13]	魏俊吉. 神经外科重症医学规范化诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(6): 477-478.
[14]	杜倩, 邓素君, 邹姗, 金珺, 周青山. 宏基因组第二代测序技术在重症中枢神经系统感染中的应用[J]. 中国现代神经疾病杂志, 2023, 23(6): 479-484.
[15]	曲鑫, 赵浩, 尚峰, 王宁. 神经重症目标温度管理[J]. 中国现代神经疾病杂志, 2023, 23(6): 485-489.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

2 CD146在血脑屏障中的作用及其机制研究进展

Research progress of the role and mechanism of CD146 in blood brain barrier

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价